Epilepsy Trial, Recruiting NCT03400371 Sponsor: King's College London Condition: Epilepsy
Back to Epilepsy

Epilepsy Trial, Recruiting

NCT03400371
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Juvenile Myoclonic Epilepsy (JME) based on agreed medical guidelines
  • Your muscle jerking (myoclonus) symptoms first started between the ages of 10 and 25
  • Your seizures mainly or only involve jerking of the arms and upper body, especially in the early morning
  • Your brain wave test (EEG) shows certain typical patterns associated with JME, with an otherwise normal background
  • You are currently between 10 and 40 years old

Who may not be able to join:

  • Your muscle jerking only happens as a result of taking the medications carbamazepine or lamotrigine
  • Your brain wave test (EEG) shows patterns that suggest a different type of epilepsy, or shows an abnormal background
  • There is any sign that your epilepsy is getting progressively worse, has a specific underlying cause, or involves focal seizures (seizures starting in one specific part of the brain)
  • You have a significant general learning disability
  • You have a condition involving distinctive physical features associated with a syndrome (confirm with trial site)
  • You are not able to give your own informed consent to take part

Please also note: This trial is currently not accepting self-referrals — you would need to be referred through a medical professional.


Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: K Pal, MD PhD, King's College London

Phone: +442078480608

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
13 July 2017
Est. completion
30 June 2026

Where this trial is recruiting

🇨🇦 Canada 🇨🇿 Czechia 🇩🇰 Denmark 🇪🇪 Estonia 🇫🇷 France 🇮🇹 Italy 🇳🇴 Norway 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Genomewide DNA association study

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov